Rosetta Biosoftware Announces the Rosetta Syllego System Version 2.0
New System Places Translational Medicine Within Researchers’ Grasp
SEATTLE–Rosetta Biosoftware, a global leader in life science informatics solutions, today announced that the Rosetta Syllego™ system version 2.0, its system for genetic studies, is now available. The newest version has been designed to create even more opportunities for researchers to see their work impact patient care.
Genetic studies combining microarray technologies, sequencing, and clinical information are poised to impact the way drugs are developed, medicine is practiced, and how patients are cared for. However, researchers still routinely encounter fundamental obstacles and gaps that prevent them from effectively translating research findings into clinical practice.
These obstacles include working with non-standardized study data from multiple platforms, accessing and implementing the most appropriate analysis method, and sharing and publishing data so that collaboration between the appropriate, distinct groups and organizations can take place. The Syllego system addresses these obstacles and provides researchers with a solution that brings together the technologies and people to solve problems and spur on the interaction between research and clinical practice.
“We’ve worked closely with our customers to understand these challenges, and our goal was to develop a system that bridges the gaps and stimulates the connection between research and clinical practice by allowing scientists to choose the best technologies to answer questions and by developing a system that brings all data, key users, and functional areas together,” said Yelena Shevelenko, General Manager of Rosetta Biosoftware.
Version 2.0 has been enhanced with an expanded set of data analysis tools and the option to use server-side processing, both of which round out the system’s new features and make the Syllego system a must-have solution for researchers and organizations engaged in genetic studies. Major pharmaceutical, research, and academic institutions around the globe are using the Syllego system, and it is also in use at the FDA as part of the VXDS (Voluntary eXploratory Data Submission) program. The newest version will be showcased at the Ninth Annual Beyond Genome conference in San Francisco, California, June 8-11, and via a series of three Rosetta Biosoftware-hosted Webinars, starting on June 12th. For more information, visit the Syllego Webinar Series registration pages at www.rosettabio.com/company/events.
About the Rosetta Syllego System
The Rosetta Syllego system is Rosetta Biosoftware’s practical solution for genetic data management and analysis. The Syllego system includes the Affymetrix GeneChip®-compatible designation and is part of the Illumina® Connect program. For more information on the Syllego system, please visit www.rosettabio.com/syllego.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Rosetta Elucidator, and Rosetta Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. More information about Rosetta Biosoftware is available at www.rosettabio.com.
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2007, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.
Rosetta Resolver, Resolver, Elucidator, and Syllego are trademarks of Rosetta Inpharmatics LLC.